Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rigel Pharmaceuticals
The primary objective of this study is:
To evaluate the efficacy of fostamatinib when used in combination with standard of care (SOC) in subjects hospitalized with COVID- 19 and requiring oxygen supplementation, as measured by days on oxygen.
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥18 years of age at screening.
The subject or a legally authorized representative has provided written informed consent.
Hospitalized COVID-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask or nasal prongs.
Male or non-pregnant, non-lactating female subjects with SARS-CoV-2 infection documented by a hospital approved diagnostic test (eg, a Food and Drug Administration authorized test in the US) within 7 days prior to randomization.
You may not be if
Pregnant or lactating female of childbearing potential.
Use of extracorporeal membrane oxygenation (ECMO).
Uncontrolled hypertension (systolic blood pressure \[BP\] ≥160 mmHg and/or diastolic BP ≥100 mmHg), unstable angina, congestive heart failure of New York Heart Association classification III or IV, serious cardiac arrhythmia requiring treatment at screening.
History of myocardial infarction within 1 month prior to screening.
Clareo Health | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
